Xenbase Image ID: 175543

Figure 5: Kmt2d loss of function inhibits MHC expression at tailbud stages. Embryos were injected with 2.5 ng MO (Kmt2d or 5 bp mismatch control) in combination with 100 pg LacZ RNA in one dorsal blastomere at the 4-cell stage. At stage 29 MHCexpression was analyzed by whole mount in situ hybridization. Embryos are shown from the ventral side; asterisks indicate the injected side. A Schematic drawing of MHCexpression at tailbud stages. First heart field (FHF) and second heart field (SHF) are indicated. B Uninjected control embryo. C Embryo injected with mismatch control MO. D Embryo injected with the Kmt2d MO showing a reduction in MHCexpression (arrow). E Kmt2d morphant embryo showing a loss of MHCexpression on the injected side (arrow). F Graph summarizing three independent injection experiments, standard errors of the means and numbers of analyzed embryos are indicated for each column. * P-value in a Student’s t-test < 0.05 Image published in: Schwenty-Lara J et al. (2019) Copyright © 2019. Image reproduced with permission of the Publisher, John Wiley & Sons. Gene Synonyms Species Stage(s) Tissue myh6.L aMHC, ck231, MHC, MHC-alpha, MHCa, MHCalpha, muz, muzak, XCMHC X. laevis Throughout NF stage 29 and 30 heart heart primordium Image source: Published Experiment + Assay Source Phenotypes and Disease Xla Wt + kmt2d MO + NF29/30 (in situ hybridization) Fig. 5 D E F Anatomical Phenotype abnormal development of heart Disease congenital heart disease Kabuki syndrome Expression Phenotype decreased amount myh6.L expression in heart Larger Image Printer Friendly View

Return to previous page